HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Julie M Vose Selected Research

carfilzomib

2/2022Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Julie M Vose Research Topics

Disease

51Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2023 - 01/2002
48Lymphoma (Lymphomas)
11/2023 - 01/2002
38Neoplasms (Cancer)
04/2024 - 10/2003
33Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
11/2021 - 10/2005
27Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
12/2023 - 03/2003
20B-Cell Lymphoma (Lymphoma, B Cell)
01/2024 - 06/2006
16Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2018 - 11/2003
13Hodgkin Disease (Hodgkin's Disease)
12/2021 - 02/2002
11Hematologic Neoplasms (Hematological Malignancy)
11/2016 - 09/2003
9Disease Progression
02/2019 - 03/2003
6Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
01/2023 - 01/2013
5B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
03/2013 - 09/2007
4Cytokine Release Syndrome
01/2024 - 12/2019
4Genetic Translocation (Chromosomal Translocation)
08/2017 - 06/2012
4Residual Neoplasm
10/2012 - 05/2002
3Febrile Neutropenia
01/2023 - 07/2005
3Thrombocytopenia (Thrombopenia)
11/2016 - 12/2006
3Burkitt Lymphoma (Burkitt's Lymphoma)
02/2015 - 06/2006
3Multiple Myeloma
05/2013 - 01/2007
3Pathologic Complete Response
09/2012 - 12/2006
2T-Cell Lymphoma (Lymphoma, T Cell)
11/2021 - 02/2010
2Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
01/2021 - 02/2010
2Anemia
06/2012 - 07/2005
2Graft vs Host Disease (Graft-Versus-Host Disease)
07/2011 - 12/2004
2Lymphoproliferative Disorders (Lymphoproliferative Disorder)
05/2009 - 01/2007
2Drug-Related Side Effects and Adverse Reactions
05/2009 - 12/2006
1Extranodal NK-T-Cell Lymphoma
03/2024
1Nausea
12/2021

Drug/Important Bio-Agent (IBA)

27Rituximab (Mabthera)FDA Link
01/2019 - 04/2006
12Cyclophosphamide (Cytoxan)FDA LinkGeneric
12/2017 - 04/2002
12Doxorubicin (Adriamycin)FDA LinkGeneric
12/2017 - 02/2002
11Vincristine (Oncovin)FDA LinkGeneric
12/2017 - 04/2002
10Prednisone (Sone)FDA LinkGeneric
12/2017 - 04/2002
8Monoclonal AntibodiesIBA
01/2015 - 01/2002
7Lenalidomide (CC 5013)FDA Link
01/2023 - 10/2008
6axicabtagene ciloleucelIBA
01/2024 - 01/2020
5Chimeric Antigen ReceptorsIBA
11/2023 - 12/2019
5Cyclin D1IBA
01/2019 - 06/2012
5Bortezomib (Velcade)FDA Link
04/2014 - 12/2010
4ibrutinibIBA
04/2024 - 08/2015
4Adrenal Cortex Hormones (Corticosteroids)IBA
01/2024 - 05/2009
4MicroRNAs (MicroRNA)IBA
11/2021 - 05/2011
4Proteins (Proteins, Gene)FDA Link
11/2021 - 07/2004
4Etoposide (VP 16)FDA LinkGeneric
02/2016 - 01/2005
4tositumomab I-131 (Bexxar)FDA Link
05/2013 - 01/2004
3Immunoconjugates (Immunoconjugate)IBA
11/2023 - 01/2002
3Agammaglobulinaemia Tyrosine KinaseIBA
11/2023 - 11/2021
3Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2023 - 02/2004
3Brentuximab VedotinIBA
12/2021 - 01/2018
3Phosphotransferases (Kinase)IBA
11/2021 - 06/2015
3Oxidoreductases (Dehydrogenase)IBA
12/2013 - 06/2012
3Carmustine (FIVB)FDA Link
05/2013 - 01/2005
3Cytarabine (Cytosar-U)FDA LinkGeneric
05/2013 - 01/2005
3Melphalan (Alkeran)FDA LinkGeneric
05/2013 - 01/2005
3AntibodiesIBA
01/2009 - 04/2003
3VaccinesIBA
10/2006 - 01/2002
2palbociclibIBA
03/2024 - 01/2019
2tocilizumab (atlizumab)FDA Link
01/2024 - 01/2021
2Bendamustine HydrochlorideFDA Link
10/2023 - 03/2011
2NivolumabIBA
12/2021 - 01/2018
2Anaplastic Lymphoma KinaseIBA
01/2021 - 02/2010
2Immunoglobulins (Immunoglobulin)IBA
01/2019 - 06/2014
2Biomarkers (Surrogate Marker)IBA
12/2015 - 12/2003
2Granulocyte Colony-Stimulating Factor (G-CSF)IBA
01/2013 - 12/2006
2ParaffinIBA
09/2012 - 05/2012
2N 30IBA
05/2012 - 11/2010
2Proteasome InhibitorsIBA
02/2011 - 02/2005
2Protein Kinase C betaIBA
05/2007 - 10/2005
2HLA Antigens (Human Leukocyte Antigens)IBA
02/2007 - 09/2003
2IodineIBA
06/2005 - 01/2004
1GemcitabineFDA Link
03/2024
1brexucabtagene autoleucelIBA
10/2023
1Immunomodulating AgentsIBA
01/2023
1Biosimilar PharmaceuticalsIBA
01/2023
1Complement System Proteins (Complement)IBA
11/2022
1Circulating Tumor DNAIBA
11/2022
1carfilzomibIBA
02/2022
1UbiquitinIBA
01/2022
1Proteasome Endopeptidase Complex (Proteasome)IBA
01/2022
1Messenger RNA (mRNA)IBA
11/2021
1SphingolipidsIBA
11/2021
1Mechanistic Target of Rapamycin Complex 1IBA
11/2021
1vistusertibIBA
11/2021
1acalabrutinibIBA
11/2021

Therapy/Procedure

68Therapeutics
04/2024 - 01/2002
29Drug Therapy (Chemotherapy)
03/2024 - 05/2002
18Hematopoietic Stem Cell Transplantation
01/2019 - 05/2002
16Stem Cell Transplantation
01/2023 - 12/2004
15Transplantation
01/2023 - 04/2003
12Cell Transplantation
12/2021 - 05/2006
8Autologous Transplantation
11/2014 - 05/2002
7Immunotherapy
01/2017 - 01/2004
5Radioimmunotherapy
05/2013 - 04/2003
4Salvage Therapy
12/2021 - 07/2011
3Radiotherapy
03/2024 - 02/2005
3Aftercare (After-Treatment)
05/2009 - 02/2005
2Highly Active Antiretroviral Therapy (HAART)
02/2015 - 11/2012
2Homologous Transplantation
11/2012 - 08/2012
2Bone Marrow Transplantation (Transplantation, Bone Marrow)
04/2005 - 04/2003
1Precision Medicine
11/2022